Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment

Nat Commun. 2018 Apr 3;9(1):1305. doi: 10.1038/s41467-018-03733-8.

Abstract

Exosomes are cell-derived nanovesicles (50-150 nm), which mediate intercellular communication, and are candidate therapeutic agents. However, inefficiency of exosomal message transfer, such as mRNA, and lack of methods to create designer exosomes have hampered their development into therapeutic interventions. Here, we report a set of EXOsomal transfer into cells (EXOtic) devices that enable efficient, customizable production of designer exosomes in engineered mammalian cells. These genetically encoded devices in exosome producer cells enhance exosome production, specific mRNA packaging, and delivery of the mRNA into the cytosol of target cells, enabling efficient cell-to-cell communication without the need to concentrate exosomes. Further, engineered producer cells implanted in living mice could consistently deliver cargo mRNA to the brain. Therapeutic catalase mRNA delivery by designer exosomes attenuated neurotoxicity and neuroinflammation in in vitro and in vivo models of Parkinson's disease, indicating the potential usefulness of the EXOtic devices for RNA delivery-based therapeutic applications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3' Untranslated Regions
  • Animals
  • Brain / metabolism
  • Catalase / metabolism
  • Cell Communication
  • Cell Line, Tumor
  • Cerebrum / metabolism
  • Cerebrum / pathology*
  • Cytosol / metabolism
  • Drug Delivery Systems*
  • Electroporation
  • Exosomes / metabolism*
  • Female
  • Genetic Therapy
  • HEK293 Cells
  • HeLa Cells
  • Humans
  • Mesenchymal Stem Cells / metabolism
  • Mice
  • Mice, Inbred C57BL
  • MicroRNAs
  • Nanoparticles
  • Parkinson Disease / therapy*
  • RNA, Messenger / metabolism
  • Synthetic Biology

Substances

  • 3' Untranslated Regions
  • MicroRNAs
  • RNA, Messenger
  • Catalase